Merck Spins Out Biosimilars And Legacy Brands
New Company To Include Women’s Health, Legacy Brands And Biosimilars
Merck has announced plans to spin off its Biosimilars, Women’s Health and Legacy Brands units into a separate company.
You may also be interested in...
After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.
The planned spin-off of Merck & Co’s Organon unit, with annual sales of $6.5bn including from biosimilars, is nearing completion, with the originator filing documentation with the SEC and unveiling a progressive female-majority board of directors for the new company.
While in possession of a token biosimilar portfolio and pipeline, Sanofi has made it clear that its R&D dollars are unlikely to be spent on biosimilars, six months after reshaping its pipeline by exiting diabetes and cardiovascular diseases research.